Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli : a post hoc analysis of the FOREST randomized trial
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Fosfomycin is a potentially attractive option as step-down therapy for bacteraemic urinary tract infections (BUTI), but available data are scarce. Our objective was to compare the effectiveness and safety of fosfomycin trometamol and other oral drugs as step-down therapy in patients with BUTI due to MDR Escherichia coli (MDR-Ec).
METHODS: Participants in the FOREST trial (comparing IV fosfomycin with ceftriaxone or meropenem for BUTI caused by MDR-Ec in 22 Spanish hospitals from June 2014 to December 2018) who were stepped-down to oral fosfomycin (3 g q48h) or other drugs were included. The primary endpoint was clinical and microbiological cure (CMC) 5-7 days after finalization of treatment. A multivariate analysis was performed using logistic regression to estimate the association of oral step-down with fosfomycin with CMC adjusted for confounders.
RESULTS: Overall, 61 patients switched to oral fosfomycin trometamol and 47 to other drugs (cefuroxime axetil, 28; amoxicillin/clavulanic acid and trimethoprim/sulfamethoxazole, 7 each; ciprofloxacin, 5) were included. CMC was reached by 48/61 patients (78.7%) treated with fosfomycin trometamol and 38/47 (80.9%) with other drugs (difference, -2.2; 95% CI: -17.5 to 13.1; P = 0.38). Subgroup analyses provided similar results. Relapses occurred in 9/61 (15.0%) and 2/47 (4.3%) of patients, respectively (P = 0.03). The adjusted OR for CMC was 1.11 (95% CI: 0.42-3.29, P = 0.75). No relevant differences in adverse events were seen.
CONCLUSIONS: Fosfomycin trometamol might be a reasonable option as step-down therapy in patients with BUTI due to MDR-Ec but the higher rate of relapses would need further assessment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
The Journal of antimicrobial chemotherapy - 78(2023), 7 vom: 05. Juli, Seite 1658-1666 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sojo-Dorado, Jesús [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
023C2WHX2V |
|---|
| Anmerkungen: |
Date Completed 06.07.2023 Date Revised 11.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jac/dkad147 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357623975 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357623975 | ||
| 003 | DE-627 | ||
| 005 | 20240114233726.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jac/dkad147 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM357623975 | ||
| 035 | |a (NLM)37260299 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sojo-Dorado, Jesús |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli |b a post hoc analysis of the FOREST randomized trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2023 | ||
| 500 | |a Date Revised 11.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Fosfomycin is a potentially attractive option as step-down therapy for bacteraemic urinary tract infections (BUTI), but available data are scarce. Our objective was to compare the effectiveness and safety of fosfomycin trometamol and other oral drugs as step-down therapy in patients with BUTI due to MDR Escherichia coli (MDR-Ec) | ||
| 520 | |a METHODS: Participants in the FOREST trial (comparing IV fosfomycin with ceftriaxone or meropenem for BUTI caused by MDR-Ec in 22 Spanish hospitals from June 2014 to December 2018) who were stepped-down to oral fosfomycin (3 g q48h) or other drugs were included. The primary endpoint was clinical and microbiological cure (CMC) 5-7 days after finalization of treatment. A multivariate analysis was performed using logistic regression to estimate the association of oral step-down with fosfomycin with CMC adjusted for confounders | ||
| 520 | |a RESULTS: Overall, 61 patients switched to oral fosfomycin trometamol and 47 to other drugs (cefuroxime axetil, 28; amoxicillin/clavulanic acid and trimethoprim/sulfamethoxazole, 7 each; ciprofloxacin, 5) were included. CMC was reached by 48/61 patients (78.7%) treated with fosfomycin trometamol and 38/47 (80.9%) with other drugs (difference, -2.2; 95% CI: -17.5 to 13.1; P = 0.38). Subgroup analyses provided similar results. Relapses occurred in 9/61 (15.0%) and 2/47 (4.3%) of patients, respectively (P = 0.03). The adjusted OR for CMC was 1.11 (95% CI: 0.42-3.29, P = 0.75). No relevant differences in adverse events were seen | ||
| 520 | |a CONCLUSIONS: Fosfomycin trometamol might be a reasonable option as step-down therapy in patients with BUTI due to MDR-Ec but the higher rate of relapses would need further assessment | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Fosfomycin |2 NLM | |
| 650 | 7 | |a 2N81MY12TE |2 NLM | |
| 650 | 7 | |a Tromethamine |2 NLM | |
| 650 | 7 | |a 023C2WHX2V |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a López-Hernández, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Torres, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Retamar-Gentil, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Merino de Lucas, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Escolà-Vergé, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Bereciartua, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a García-Vázquez, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Pintado, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Boix-Palop, Lucía |e verfasserin |4 aut | |
| 700 | 1 | |a Natera-Kindelán, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Sorlí, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Borrell, Nuria |e verfasserin |4 aut | |
| 700 | 1 | |a Amador-Prous, Concha |e verfasserin |4 aut | |
| 700 | 1 | |a Shaw, Evelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Jover-Saenz, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Molina, Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Álvarez, Rosa M |e verfasserin |4 aut | |
| 700 | 1 | |a Dueñas, Carlos J |e verfasserin |4 aut | |
| 700 | 1 | |a Calvo-Montes, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Lecuona, María |e verfasserin |4 aut | |
| 700 | 1 | |a Pomar, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Borreguero, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Palomo-Jiménez, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Docobo-Pérez, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Pascual, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Baño, Jesús |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g 78(2023), 7 vom: 05. Juli, Seite 1658-1666 |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:7 |g day:05 |g month:07 |g pages:1658-1666 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dkad147 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 7 |b 05 |c 07 |h 1658-1666 | ||